Cargando…

A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)

Background: Coronavirus disease 2019 is a global public health concern. As of December 2020, the therapeutic agents approved for coronavirus disease 2019 in Japan were limited to two drugs: remdesivir, an antiviral drug, granted a Special Approval for Emergency on 7 May 2020, and dexamethasone, whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomita, Noriko, Saito, Sho, Terada-Hirashima, Junko, Mikami, Ayako, Uemura, Yukari, Kutsuna, Satoshi, Nomoto, Hidetoshi, Fujisawa, Kyoko, Nagashima, Maki, Terada, Mari, Ashida, Shinobu, Morioka, Shinichiro, Satake, Masahiro, Hangaishi, Akira, Togano, Tomiteru, Shiratori, Katsuyuki, Takamatsu, Yuki, Maeda, Kenji, Ohmagari, Norio, Sugiura, Wataru, Mitsuya, Hiroaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225318/ https://www.ncbi.nlm.nih.gov/pubmed/35743887 http://dx.doi.org/10.3390/life12060856

Ejemplares similares

Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma
por: Inada, Makoto, et al.
Publicado: (2023)

Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals
por: Terada, Mari, et al.
Publicado: (2023)

Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial
por: Saito, Sho, et al.
Publicado: (2023)

Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved
por: Suzuki, Tetsuya, et al.
Publicado: (2023)

The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan
por: Kamo-Imai, Ayumi, et al.
Publicado: (2023)

The influence of pre-admission antiplatelet and anticoagulation therapy on the illness severity in hospitalized patients with COVID-19 in Japan
por: Togano, Tomiteru, et al.
Publicado: (2021)

Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial
por: Terada-Hirashima, Junko, et al.
Publicado: (2020)

Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan
por: Suzuki, Tetsuya, et al.
Publicado: (2022)

Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
por: Inada, Makoto, et al.
Publicado: (2022)

SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
por: Kamegai, Kohei, et al.
Publicado: (2022)

Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox
por: Suzuki, Tetsuya, et al.
Publicado: (2023)

Factors Associated With Prolonged Psychological Distress Among Nurses and Physicians Engaged in COVID-19 Patient Care in Singapore and Japan
por: Morioka, Shinichiro, et al.
Publicado: (2022)

Adapting the randomised controlled trial (RCT) for precision medicine: introducing the nested-precision RCT (npRCT)
por: Kappelmann, Nils, et al.
Publicado: (2021)

Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019
por: Miyazato, Yusuke, et al.
Publicado: (2020)

Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan
por: Hara, Hisao, et al.
Publicado: (2021)

Conjunctivitis, the key clinical characteristic of adult rubella in Japan during two large outbreaks, 2012–2013 and 2018–2019
por: Nomoto, Hidetoshi, et al.
Publicado: (2020)

Correction: Conjunctivitis, the key clinical characteristic of adult rubella in Japan during two large outbreaks, 2012–2013 and 2018–2019
por: Nomoto, Hidetoshi, et al.
Publicado: (2022)

Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants
por: Tsuchiya, Kiyoto, et al.
Publicado: (2023)

Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies
por: Inada, Makoto, et al.
Publicado: (2021)

Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients
por: Tsuzuki, Shinya, et al.
Publicado: (2022)

Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities
por: Tomidokoro, Daiki, et al.
Publicado: (2023)

480. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant among Immunocompromised Patients
por: KAMEGAI, K O H E I, et al.
Publicado: (2023)

Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA)
por: Terayama, Yuriko, et al.
Publicado: (2022)

We Should Pay More Attention to Sex Differences to Predict the Risk of Severe COVID-19: Men Have the Same Risk of Worse Prognosis as Women More Than 10 Years Older
por: Matsushita, Yumi, et al.
Publicado: (2023)

Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan
por: Terada, Mari, et al.
Publicado: (2021)

Speech treatment in Parkinson's disease: Randomized controlled trial (RCT)
por: Ramig, Lorraine, et al.
Publicado: (2018)

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
por: Maeda, Kenji, et al.
Publicado: (2021)

No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity
por: Nomoto, Hidetoshi, et al.
Publicado: (2021)

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19
por: Miyazato, Yusuke, et al.
Publicado: (2022)

Factors associated with development and persistence of post-COVID conditions: A cross-sectional study()
por: Miyazato, Yusuke, et al.
Publicado: (2022)

A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies
por: Noda, Kenta, et al.
Publicado: (2021)

452. Spectrum of Respiratory Pathogens Detected by Multiplex PCR in a Study of Respiratory Tract Infections Among Travelers
por: Kutsuna, Satoshi, et al.
Publicado: (2018)

Leuconostoc lactis and Staphylococcus nepalensis Bacteremia, Japan
por: Hosoya, Satoshi, et al.
Publicado: (2020)

Review of an innovative approach to practical trials: the ‘cohort multiple RCT’ design
por: Relton, Clare, et al.
Publicado: (2015)

Participants’ understanding of a randomized controlled trial (RCT) through informed consent procedures in the RCT for breast cancer screening, J-START
por: Shiono, Yoko Narikawa, et al.
Publicado: (2014)

Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan
por: Matsunaga, Nobuaki, et al.
Publicado: (2020)

AF1q inhibited T cell attachment to breast cancer cell by attenuating Intracellular Adhesion Molecule-1 expression
por: Park, Jino, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jhhqgr8kt9aqcct5nh0alfoc22